The Impact of Histological Types on the Efficacy of Angiogenesis Inhibitors in the Treatment of Advanced NSCLC: A Meta-Analysis of Randomized Controlled TrialsOctober 15, 2015
This research assesses the overall efficacy of angiogenesis inhibitor (AI)-containing regimens in the treatment of advanced non-small-cell lung cancer (NSCLC).
Scientists believe that targeting blood vessel cells known as pericytes may offer a potential new therapeutic approach for breast and other cancers.
A novel DNA vaccine is being employed to kill cancer, not by attacking tumor cells, but by targeting the blood vessels that keep them alive.
This fact sheet reviews the use of angiogenesis inhibitors to prevent the formation of new blood vessels, in order to stop or slow the growth or spread of cancerous tumors.
Computerized tomography adds to lactate dehydrogenase (LDH) levels in predicting survival among persons with metastatic melanoma on bevacizumab.
News from the FDA on bosutinib (Bosulif), ziv-aflibercept (Zaltrap), and everolimus oral suspension tablets (Afinitor Disperz).
Thiabendazole, an antifungal drug in clinical use for 40 years, inhibits angiogenesis, slows tumor growth, and reduces vascular density of tumors.
New research is showing that sequence and timing have significant impact on the efficacy of therapeutic regimens that include bevacizumab.
A newly identified subtype of ovarian cancer that builds its own blood vessels may be vulnerable to agents that block blood vessel formation.
The investigational drug regorafenib conferred a statistically significant survival benefit in patients with metastatic colorectal cancer in whom no standard therapy was effective.
The use of bevacizumab (Avastin) improved progression-free survival in women with ovarian cancer, particularly those at high risk for disease progression.
The FDA has revoked its approval of the breast cancer indication for Avastin (bevacizumab). The anti-angiogenic therapy remains indicated for some colorectal, lung, brain, and kidney cancers.
Using bevacizumab in combination with chemotherapy or biological therapy raises the risk of treatment-related death—but the agent's potential benefits may outweigh the relatively low absolute risk.
A naturally occurring protein inhibits tumor growth and metastasis into secondary organs and has the potential to be developed into an anticancer drug, scientists have found.
Doctors who monitor and help control a patient's blood pressure can minimize the side effects of novel cancer drugs, according to a paper published in the Journal of the National Cancer Institute (2010 May 5;102(9):596-604).
Targeting tumor vasculature by inhibiting angiogenesis is a promising approach for women with advanced ovarian cancer, and clinical trials should designed to ensure that novel agents are evaluated rapidly
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- Screening Recommendations for Children with Common Cancer Predisposition Syndromes
- Significance of Prostate Cancer Treatment-Related Factors Differ in Black, White Men
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Superior Tolerability, Efficacy With Alectinib in Treatment-Naïve ALK-poistive NSCLC
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Lack of Transfusion Services a Barrier to Hospice Care for Patients With Blood Cancers
- Aspirin Use May Lower Breast Cancer Risk in Women with Diabetes
- Ethnic Differences, Cultural Barriers Negatively Impact Mammography Follow-up Among Asian Ethnic Groups
- Study Questions Safety of E-cigarettes vs Regular Tobacco Cigarettes
- Changes in Pulmonary Function Tests in Breast Carcinoma Patients Treated With Locoregional Post-mastectomy Radiotherapy: Results of a Pilot Study
- Increases in Liver Cancer Incidence Influenced by Higher Rates of Comorbidities
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|